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Objective: The purpose of this study was to estimate the cost-effectiveness of memantine 
relative to standard care in patients with moderate-to-severe Alzheimer’s disease in the 
Netherlands.
Methods: A country-adapted five-year Markov model simulated disease progression through 
a series of states, defined by dependency and disease severity. Transition probabilities were 
derived from trials, with utility and epidemiological data obtained from a longitudinal Dutch 
cohort. Cost-effectiveness was described in terms of quality-adjusted life years and time spent 
in a nondependent state or in a moderate severity state.
Results: Memantine monotherapy versus standard care led to 0.058 quality-adjusted life years 
gained (1.207 versus 1.265), longer time in a nondependent state (from 1.602 to 1.751 years) 
and in a moderate state (from 2.051 to 2.141 years), and no additional costs (€113,927 versus 
€110,097). Robustness of results was confirmed through sensitivity analyses.
Conclusion: Memantine is dominant compared with standard care in the Netherlands. Results 
are consistent with similar economic evaluations in other countries.
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Introduction
Alzheimer’s disease is the most common cause of dementia, accounting for  two-thirds 
of all dementia cases. People with Alzheimer’s disease experience gradual loss of 
independence, and as Alzheimer’s disease becomes more severe, the burden on 
informal caregivers increases until institutionalization is required. A study in the 
Netherlands showed that dementia patients spend approximately 20–25% of their time 
 institutionalized with the condition.1
Previous pharmacoeconomic studies conducted in the Netherlands have investigated 
galantamine, an acetylcholinesterase inhibitor, for mild-to-moderate Alzheimer’s 
disease and the general costs associated with the disease.2,3
Memantine is a moderate-aff inity, noncompetitive N-methyl-D-aspartate 
antagonist, and is approved in over 70 countries worldwide for the symptomatic 
treatment of patients with moderate-to-severe Alzheimer’s disease. Memantine may 
be administered as monotherapy or in combination with an acetylcholinesterase 
inhibitor. In this study, a Markov model was used to determine the cost-effectiveness 
of memantine relative to standard care in moderate-to-severe Alzheimer’s disease 
in the Netherlands.
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Methods
This cost-effectiveness study evaluated the f ive-year 
 outcomes associated with memantine monotherapy compared 
with no pharmacological treatment (standard care) in terms 
of additional time living independently, additional time in a 
moderate state, quality-adjusted life years, and societal costs. 
A Markov model adapted from a previous model constructed 
for the Canadian setting was used, and full methodological 
details are provided in Gagnon et al.4 The methods employed 
here are identical to the Canadian model unless explicitly 
stated otherwise. Key changes are the data source for the 
initial patient distribution, background mortality, cost per 
health state, and discount rates. Each of these inputs was 
adjusted to make the model directly relevant to the economic 
assessment of memantine in the Netherlands as described by 
the College Voor Zorgverzekeringen (CVZ).5
Model structure
In this model, health states were based on dependence and 
Alzheimer’s disease severity, ie, a patient could be in one 
of five possible states: moderate, independent;  moderate, 
dependent; severe, independent; severe, dependent; death. 
A six-month Markov cycle was chosen and repeated 
10 times.
Perspective
This study was performed from a societal perspective, with 
nonmedical costs included, in line with the CVZ guidelines 
for pharmacoeconomic research.
Data sources
The initial patient distributions between Markov health states 
were computed from the Rotterdam study.6 This was a large 
study testing 7528 residents (2939 men and 4589 women) 
aged 55 years and over (median age 69 years) of a  Rotterdam 
suburb for disorders associated with  dementia. The  Rotterdam 
study found a subset of 339 patients diagnosed with 
Alzheimer’s disease, from which the health state distributions 
were calculated.7 The  percentages of patients by severity stage 
and level of dependency were:  moderate severity, independent 
(69.02%); moderate, dependent (20.11%); severe, indepen-
dent (6.52%); and severe, dependent (4.35%).
All severity and dependency transition probabilities 
were assumed to depend only on patient severity and 
dependency stages at the beginning of the cycle and on 
treatment, and were estimated using pooled data from four 
six-month, double-blind, randomized, placebo-controlled 
clinical trials for memantine considering a total of 1096 
patients with moderate-to-severe Alzheimer’s disease (589 
receiving memantine and 507 receiving placebo).8–11 The 
efficacy of memantine was assumed to last for the first 
12 months of treatment, as suggested by an open-label 
extension study.12
Probability of death over each six-month cycle was 
assumed to be the same for all Markov health states and 
treatment strategies, and was computed from published Dutch 
data.3 This resulted in an estimated probability of death of 
7.55% for each six-month period when data were adjusted 
using the weighted mean of probabilities. This was based on 
the aforementioned initial model distribution for dependency 
status and an assumption (based on expert opinion) that, for 
patients in an institution, the split between patients living in 
a home for the elderly and patients living in a nursing home 
was 2/3:1/3 in independent patients and 1/2:1/2 in dependent 
patients. The uncertainty surrounding these parameters was 
modeled using a priori triangular distributions.
The costs per unit of care were derived from the Dutch 
guidelines.13 The number of units used per health state was 
estimated from a Dutch model of cost of care for patients 
with dementia.14 The costs of care and consumption by 
dependency and type of accommodation were calculated 
in Euros (€, value 1999, Table 1). Because no distinction 
between genders was made in this study, it was assumed 
when calculating total cost per stage that approximately 66% 
of the patients with Alzheimer’s disease were female, based 
on dementia prevalence estimates among men and women 
from the Rotterdam study.6
The distribution of moderate and severe Alzheimer’s 
disease patients in the Rotterdam study and the split between 
patients living in a home for the elderly and patients living 
in a nursing home were applied to costs per dependency and 
accomodation (Table 1), to compute the costs per Markov 
health state. Costs were updated to 2008 using the consumer 
price data from Statistics Netherlands restricted to the health 
sector. Final six-month cost estimates per Markov health 
state were 8,092.12 (EUR, 2008) for moderate independent 
patients, 26,202.87 for moderate dependent, 9,475.97 for 
severe independent and 27,022.75 for severe dependent. The 
price used for memantine in the Netherlands was €2.95 per 
defined-daily-dose of 20 mg. An additional pharmacist fee of 
€6.10 per prescription was added. The cost of the memantine 
treatment over a cycle was €537.10.
Level of dependency and residential status appear to 
be the main criteria influencing quality-adjusted life years 
values, and thus values were taken from the LASER-AD 
study from the UK that considered 224 Alzheimer’s disease 
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Table 1 Annual costs and consumption (€, value 1999) by dependency and accommodation
Stage Accommodation Type of care Costs/unit* Units† Costs
independent community general practitioner 16.59 euro/consult 6.09 consults 101.03 euro
Family care 17.70 euro/hour 93.59 hours 1656.54 euro
District-nursing 31.76 euro/hour 17.51 hours 556.12 euro
riAgg 102.55 euro/contact – –
Hospital admission1 283.84 euro/day – –
Day-care center  
(including travelling costs)
52.18 euro/day – –
informal care 7.94 euro/hour 260 hours 2064.40 euro
Total – – 4378.09 euro
Home for the elderly2 Total 30.33 euro/day 365 days 11070.45 euro
Nursing home2 Total 99.43 euro/day3 365 days 36291.95 euro
Dependent community general practitioner 16.59 euro/hour 6.09 consults 101.03 euro
Family care 17.70 euro/hour 183.22 hours 3242.99 euro
District nursing 31.76 euro/hour 213.53 hours 6781.71 euro
riAgg 102.55 euro/contact 9.4 contacts 963.97 euro
Hospital admission 283.84 euro/day 41.65 days 11821.94 euro
Day-care center  
(including travelling costs)
52.18 euro/day 92 days 4800.56 euro
informal care 7.94 euro/hour 322 hours 2556.68 euro
Total – – 30268.88 euro
Home for the elderly2 Total 94.01 euro/day 365 days 34313.65 euro
Nursing home2 Total 171.02 euro/day3 365 days 62422.30 euro
Notes: 1Mean academic and general hospital; 2These do not include housing costs; 3Mean psychogeriatric and combined nursing homes; *Derived from Oostenbrink et al;13 
†Derived from Van der roer.14
Abbreviation: riAgg, regional institutes for mental health.
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patients (independent in community, 0.608 [standard error 
(SE) 0.028]; independent in institution, 0.543 [SE 0.064]; 
dependent in community. 0.340 [SE 0.058]; dependent in 
institution, 0.169 [SE 0.058]).15
Following Dutch guidelines, health outcomes were dis-
counted at an annual rate of 1.5%, and costs outcomes at 4%.
Analyses
The base-case scenario reported the mean number of years of 
independence and moderate severity state, quality-adjusted life 
years and average costs over five years. Probabilistic analyses 
using Monte-Carlo simulations comprised of 10,000 draws 
were conducted, which attributed a value for each of the a 
priori distributions. The a priori distributions were beta distri-
butions for severity and dependency transition probabilities, 
log-normal for the odds ratios measuring impact of memantine 
on severity and dependency transitions, normal distributions 
for utilities per health states, triangular for the nursing home/
home for elderly proportions, and triangular (±20%) for costs 
per health states. A worst-case scenario was included whereby 
it was assumed that patients received treatment for two years, 
but the treatment effect only lasted for six months. One-way 
sensitivity analyses were conducted on the odds ratios of 
memantine applied to dependency and severity probabilities. 
A sensitivity analysis was also  conducted on the discount rates 
(applied to both costs and health benefits) by using the values 
0% and 7% per annum in the model. Finally, a sensitivity 
analysis was conducted on the nursing home/home for elderly 
distributions.
Results
Compared with the standard care strategy, over five years 
memantine treatment produced an additional 0.149 years 
(54.39 days, 95% credible intervals [Crl] = 0.036; 0.252) of 
independence, 0.091 years (33.22 days, 95% Crl = −0.027; 
0.197) in the moderate disease state, and 0.058 (95% 
Crl = 0.014; 0.108) additional quality-adjusted life years 
(Table 2). Furthermore, memantine treatment was associated 
with a cost reduction of €3,830 compared with standard care. 
Memantine was the dominant strategy being more effective 
and less costly than standard care. There was a 96.8% 
probability of memantine being dominant.
Results were robust to sensitivity analyses. For the worst-
case scenario, the memantine strategy was associated with 
an additional 0.078 years (28.47 days; 95% Crl = 0.019; 
0.132) of independence, 0.048 years (17.52 days; 95% 
Crl = −0.015; 0.104) in the moderate disease state, and 0.031 
additional quality-adjusted life years (95% Crl = 0.007; 
0.057). Memantine was associated with a cost reduction of 
€920 over the five-year evaluation period compared with 
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Table 2 The cost-effectiveness model outcomes of memantine compared with standard care
Memantine Standard care
Mean 2.5%; 97.5% CrI Mean 2.5%; 97.5% CrI
Distribution of model outcomes and costs per strategy
 QALYs 1.265 0.999; 1.527 1.207 0.940; 1.471
 Years in independent state 1.751 1.463; 2.039 1.602 1.335; 1.878
 Years in moderate state 2.141 1.852; 2.415 2.051 1.780; 2.322
 costs (€, value 2006) 110,097 96,599; 124,223 113,927 100,364; 128,146
Distribution of incremental model outcomes and costs associated with memantine
 QALYs 0.058 0.014; 0.108
 Years in independent state 0.149 0.036; 0.252
 Years in moderate state 0.091 −0.027; 0.197
 costs (€, value 2006) −3,830 −7,793; 208
Abbreviations: cri, credible interval; QALYs, quality-adjusted life years.
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standard care. The probability of memantine being dominant 
was 80.7% in this scenario.
Discussion
This study has shown that over a five-year period in a 
Dutch setting, compared with standard care in patients 
with moderate-to-severe Alzheimer’s disease, memantine 
was associated with additional quality-adjusted life years, 
prolonged time of independence and prolonged time in the 
moderate Alzheimer’s disease state.
These health benefits translated into cost savings, which 
fully offset the drug cost, making memantine the dominant 
option. The internal validity and robustness of the model were 
ensured through numerous sensitivity analyses conducted 
around key parameters. A major assumption is that the 
structure of the Canadian model and several inputs are con-
sidered generalizable without transferability adaptation.16
This study confirmed results from previous cost- 
effectiveness analyses performed in other countries such as the 
UK, Finland, Norway, Sweden, Spain, and Canada. In each of 
these evaluations, the additional cost of memantine was offset 
by health benefits which translated into cost  savings. Results 
were consistent, despite differences in model design, perspec-
tive, data sources, geographical location, and time horizon. 
The estimated gain in terms of months of independence 
(increase of 9.3% for 1.8 months) in this study was similar 
to other evaluations of memantine. Although not directly 
comparable, it is interesting to note that in an analysis of 
galantamine for Alzheimer’s disease in a number of  countries 
(including the Netherlands), galantamine delayed time to full-
time care by 6.8%.17 As with all pharmacoeconomic analyses, 
this cost-effectiveness evaluation is subject to a number of 
limitations because it extrapolates data from the clinical trial 
setting to model real-life practice and is associated with a 
number of assumptions.
Conclusion
This analysis demonstrated that memantine monotherapy 
produced health benefits compared with standard care which 
translated into cost savings. Memantine was associated with 
additional quality-adjusted life years and an extended period 
of nondependence. These results for the Netherlands are con-
sistent with economic evaluations of memantine in Canada 
and a number of other countries in Europe.
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